- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Nonprofit Payer Says It Saved $1.7 Million Through Use of Infliximab Biosimilars
Health New England says it achieved 93% utilization by requiring prior authorization.
A nonprofit health plan in Massachusetts recently said it has saved $1.7 million over the past year since emphasizing use of biosimilar infliximab, reaching 93% utilization in collaboration with Magellan Rx Management.
Health New England said its medical pharmacy program began the initiative on January 1, 2019.
“We were looking for ways to drive cost savings in this class without compromising patient care,” said Andrew J. Colby, RPh, MBA, Health New England's pharmacy director, in a recent statement. “Biosimilars offer an important opportunity to reduce costs for both payers and patients, while ensuring patients can continue treatment with a product that provides the same levels of clinical efficacy and safety they have experienced while taking the innovator drug.”
The reference product, Remicade, remains the highest-spend drug on the medical benefit, the company said. Biosimilars can cost as much as 35% less than originator products, the company noted.
Payers spend approximately $43,000 per patient annually on this product, and expenditures have continued to grow, including a 14% increase in Remicade per-member-per-month (PMPM) spend for commercial health plans from 2016 to 2017, according to Magellan.
Autoimmune PMPM drug costs are expected to increase 90%, from $1.40 to $2.66, by 2022 Magellan noted in last year’s Medical Pharmacy Trends report.
Working with Magellan, Health New England said it turned to a prior authorization program to drive utilization to biosimilar infliximab, with pharmacists using “the most updated peer-reviewed literature to develop a robust clinical policy.”
“We were able to collaborate with our provider network to ensure a smooth transition to the biosimilar product while providing patients with the same quality of care,” said Colby. “Our positive experience with this effort further supports similar initiatives for other therapeutic categories, such as oncology, in mitigating rising medical benefit trend and spend.”
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
January 31st 2025The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.
